United States. Securities and Exchange Commission
Ginkgo Bioworks Holdings, Inc., a biotech company, has filed a Form 144 with the U.S. Securities and Exchange Commission (SEC), disclosing plans to sell restricted securities. The filing, which was made on August 14, 2023, indicates that the company intends to sell securities held by an affiliate in reliance
United States. Securities and Exchange Commission
Amgen Inc., a leading biopharmaceutical company, submitted a significant filing with the U.S. Securities and Exchange Commission (SEC) on August 3, 2023. The filing, identified by the SEC file number 0000318154-23-000049, contains 15 documents that provide crucial information about the company's recent events and corporate changes. As
United States. Securities and Exchange Commission
Moderna, Inc., a leading biotechnology company, has filed its Form 10-Q with the U.S. Securities and Exchange Commission (SEC) on August 3, 2023. The filing, which was reported by NewsRx journalists, includes unaudited financial statements and provides a continuing view of the company's financial position during the
United States. Securities and Exchange Commission
Humacyte, Inc. has filed a simplified registration form with the U.S. Securities and Exchange Commission (SEC), indicating its intentions to raise capital or engage in other financial activities. The filing, noted in a SEC document on June 9, 2023, reflects the company's status as a biopharmaceutical entity,
United States. Securities and Exchange Commission
At its annual meeting on June 22, 2023, Acorda Therapeutics stockholders elected Thomas Burns to the company's Board of Directors, with his term set to expire at the 2026 annual meeting. Burns will receive compensation under the company's non-employee director compensation policy, including cash and an
United States. Securities and Exchange Commission
Sutro Biopharma, Inc. has reported the resignation of Shalini Sharp as a Class III director and Chair of the Audit Committee, effective immediately, on April 10, 2023. Sharp's resignation did not result from any disagreements with the company's management or the Board. In her place, Heidi
United States. Securities and Exchange Commission
Vaxcyte, a clinical-stage vaccine innovation company, has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering, which is subject to market and regulatory conditions, aims to raise funds to support the company's continued growth and development of its high-fidelity vaccines. Joint book-running managers
United States. Securities and Exchange Commission
Amgen Inc., a biopharmaceutical company, has made a significant filing with the U.S. Securities and Exchange Commission (SEC) on March 9, 2023, through Form 8-K, the "current report" used to disclose material events or corporate changes. This filing was made available to the public through the SEC&
United States. Securities and Exchange Commission
Caribou Biosciences, Inc., a biotechnology company, has reported a material event through a U.S. Securities and Exchange Commission (SEC) filing. The filing, submitted on March 9, 2023, reveals a significant occurrence that affects investors or security holders. This event is detailed in a "current report" submitted using
United States. Securities and Exchange Commission
According to a recent SEC filing, Amgen Inc. disclosed a significant update related to the company's leadership and corporate structure. The filing, submitted on March 8, 2023, provides insight into the company's compliance with US securities regulations. As a major biopharmaceutical company, Amgen Inc. is subject
United States. Securities and Exchange Commission
A U.S. Securities and Exchange Commission (SEC) filing by Seagen Inc. on March 3, 2023, revealed a notable disclosure. The SIC code for this company is 2836, Biological Products, specifically excluding Diagnostic Substances. As per the SEC filing, Seagen Inc.'s contact information is 21823 30TH DRIVE SE,
United States. Securities and Exchange Commission
A U.S. Securities and Exchange Commission (SEC) filing by Fate Therapeutics Inc. was posted on February 7, 2023. The company, operating in the biopharmaceutical industry, submitted a single document with form 4, which reports on transactions involving directors, officers, and major shareholders. This filing is a requirement for companies
